StockData
BioNexus Gene Lab Corp logo

BioNexus Gene Lab Corp (BGLC) stock

BGLCNasdaqServices-Medical LaboratoriesFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026Score 8/3089% below fair value
$0.77−0.05 (-6.56%)

Close on Nov 17, 2026Market cap $2.25MP/E –Yield –

BioNexus Gene Lab EPS

Diluted earnings per share is net income divided by the share count including options and convertible securities.

BioNexus Gene Lab's EPS for the twelve months ending Sep 30, 2021 was $0.00. For fiscal 2024 it was -$0.09. The highest annual figure on record is $0.01 in fiscal 2020.

Annual eps

PeriodPeriod endValueChange
FY2024Dec 31, 2024-$0.09–
FY2023Dec 31, 2023-$0.17-1483.3%
FY2020Dec 31, 2020$0.01–
FY2019Dec 31, 2019$0.00–
FY2018Dec 31, 2018$0.00–

Quarterly eps

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$0.12–
Q1 FY2026Mar 31, 2026-$0.23–
Q3 FY2025Sep 30, 2025-$0.40-449.6%
Q2 FY2025Jun 30, 2025-$0.34–
Q1 FY2025Mar 31, 2025-$0.35–
Q3 FY2024Sep 30, 2024-$0.75–
Q2 FY2024Jun 30, 2024$0.11–
Q1 FY2024Mar 31, 2024-$0.01–
Q3 FY2021Sep 30, 2021$0.00–
Q2 FY2021Jun 30, 2021$0.00–
Q1 FY2021Mar 31, 2021$0.00–
Q4 FY2020Dec 31, 2020$0.00–
Q3 FY2020Sep 30, 2020$0.00–
Q2 FY2020Jun 30, 2020$0.00–
Q1 FY2020Mar 31, 2020$0.00–
Q4 FY2019Dec 31, 2019$0.00–
Q3 FY2019Sep 30, 2019$0.00–
Q2 FY2019Jun 30, 2019$0.00–
Q1 FY2019Mar 31, 2019$0.00–
Q4 FY2018Dec 31, 2018$0.00–
Q3 FY2018Sep 30, 2018$0.00–

More BioNexus Gene Lab figures

See a number that looks wrong?